CXCL12/SDF-1 beta Antibody

Recombinant Human/Feline CXCL12/SDF‑1 beta chemo­attracts the BaF3 mouse pro‑B cell line transfected with human CXCR4 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Human/Feline CXCL12/SDF‑1 beta (10 ng/mL) is neutral­ized (green line) by increasing concentrations of Goat Anti-Human CXCL12/SDF‑1 beta Anti­gen Affinity-purified Poly­clonal Antibody (Catalog # AF-351-NA). The ND50 is typically 10‑30 µg/mL.

• Reactivity: Hu
• Applications: WB, B/N
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: LYOPH

CXCL12/SDF-1 beta Antibody Summary

• Immunogen: E. coli-derived recombinant human CXCL12/SDF‑1 beta
  Lys22-Met93
  Accession # P48061
• Specificity: Detects human CXCL12/SDF‑1 beta in direct ELISAs and Western blots. Neutralizes 60‑80% of the biological activity of CXCL12/SDF-1 beta and does not neutralize the biological activity of SDF‑1 alpha . In Western blots, less than 5% cross-reactivity with recombinant human SDF-1 alpha is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: CXCL12
• Purity Statement: Antigen Affinity-purified
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • Neutralization 10-30 ug/mL
  • Western Blot 0.1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for CXCL12/SDF-1 beta Antibody

• CXCL12/SDF-1 beta
• hSDF-1beta
• SDF 1beta
• SDF1 beta
• SDF1b

Background

CXCL12, also known as SCYB12, PBSF and SDF-1 beta , is an 8.3 kDa, heparin-binding member of the CXC (or alpha-) family of chemokines (1, 2). Feline CXCL12( beta ) is synthesized as a 93 amino acid (aa) precursor that contains a 21 aa signal sequence and a 72 aa mature region (3). The mature molecule exhibits a typical three antiparallel beta -strand chemokine-like fold. There are no potential N-linked glycosylation sites. N-terminal aa’s 1 - 8 form a receptor binding site, while aa’s 1 and 2 (Lys-Pro) are involved in receptor activation (4). The C-terminus is likely associated with heparin binding (5). SDF-1 beta circulates and undergoes proteolytic processing. CD26 will remove the first two N-terminal amino acids, possibly creating a reduced-activity chemokine (5, 6). In addition to the beta -isoform, alternate splicing of the feline SDF-1 gene generates an alpha -isoform. The alpha isoform is identical to SDF-1 beta , but shorter by four aa’s at the C-terminus (3). Although alpha - and beta -isoforms show similar activity, SDF-1 alpha is differentially processed, and different cells secrete the two isoforms (5, 7). Mature feline SDF-1 beta is 96%, 97% and 100% aa identical to rat, mouse and human SDF-1 beta , respectively. Human (and by inference, feline) SDF-1 is active on mouse cells. SDF-1 alpha and beta are reported to be monomers at neutral pH and physiologic ionic strength (4). SDF-1 alpha is also reported to form dimers in the presence of heparansulfate (8). On the cell surface, this may well facilitate SDF-1 interaction with its two receptors, CXCR4 and syndecan-4 (9). Heparin sulfate is known to protect SDF-1 from proteolysis, and CXCR4 exists constitutively as a dimer (9 - 11). Among its many functions, CXCL12 is known to influence lymphopoiesis, regulate patterning and cell number of neural progenitors, and promote angiogenesis (12, 13). It also enhances the survival of myeloid progenitor cells.

1. Zlotnik, A. and O. Yoshie (2000) Immunity 12:121.
2. Rollins, B.J. (1997) Blood 90:909.
3. Nishimura, Y. et al. (1998) Eur. J. Immunogenet. 25:303.
4. Crump, M.P. et al. (1997) EMBO J. 16:6996.
5. Sierra, M.D. L. et al. (2004) Blood 103:2452.
6. Davis, D.A. et al. (2005) Blood 105:4561.
7. Stumm, R.K. et al. (2002) J. Neurosci. 22:5865.
8. Veldkamp, C.T. et al. (2005) Protein Sci. 14:1071.
9. Charnaux, N. et al. (2005) FEBS J. 272:1937.
10. Percherancier, Y. et al. (2005) J. Biol. Chem. 280:9895.
11. Babcock, G.J. et al. (2003) J. Biol. Chem. 278:3378.
12. Klein, R.S. et al. (2004) Trends Immunol. 25:306.
13. Salcedo, R. and J.J. Oppenheim (2003) Microcirculation 10:359.
14. Broxmeyer, H.E. et al. (2003) J. Leukoc. Biol. 73:630.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for CXCL12/SDF-1 beta Antibody (AF-351-NA)(1)

Publication using AF-351-NA

• Kenig S, Alonso MB, Mueller MM, Lah TT Glioblastoma and endothelial cells cross-talk, mediated by SDF-1, enhances tumour invasion and endothelial proliferation by increasing expression of cathepsins B, S, and MMP-9. Cancer Lett., 2009-08-22;289(1):53-61. 2009-08-22 [PMID: 19700239] (Neutralization, Human)

Bioinformatics

• Gene Symbol: CXCL12
• Uniprot:
  • P48061()